AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24944546 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic sodium citrate supplementation (0.1 g∙kg(-1) for three days and 0.3 g kg(-1) on the fourth day 120 min pre-trial)
Number of subjects: 10
Study 24944546 — intervention group
Group type: COMPARATOR
Intervention: Acute placebo (PLC-A)
Number of subjects: 10
Study 24944546 — intervention group
Group type: COMPARATOR
Intervention: Chronic placebo (PLC-C)
Number of subjects: 10
Study 24944934 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anti-diabetic drugs (OADs)
Number of subjects: 6168
Study 24944934 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (±OADs)
Number of subjects: 6168
Study 24944934 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes complications
Number of subjects: 6168
Study 24944934 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycaemic control
Number of subjects: 6168
Study 24944934 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to insulin therapy
Number of subjects: 6168
Study 24944934 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for structured intervention
Number of subjects: 6168
Study 24948033 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) with Carotid WALLSTENT plus FilterWire EZ Embolic Protection System
Number of subjects: 1025
Study 24948349 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 24948692 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral forodesine at a dose of 200 mg daily
Number of subjects: 144
Study 24948692 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 144
Study 24948702 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical treatment
Number of subjects: 510
Study 24948702 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive treatment
Number of subjects: 510
Study 24948702 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted treatment
Number of subjects: 510
Study 24948702 — intervention group
Group type: COMPARATOR
Intervention: Posaconazole prophylaxis
Number of subjects: 510
Study 24949622 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (ICBT) for 12 weeks with therapist support.
Number of subjects: 21
Study 24949937 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram monotherapy
Number of subjects: 2868
Study 24950186 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned Pain Modulation (CPM) assessed by the cold pressor test (CPT)
Number of subjects: 34
Study 24950352 — intervention group
Group type: EXPERIMENTAL
Intervention: First booster vaccination with Encepur(®)
Number of subjects: 323
Study 24950352 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects who had already received their booster prior to enrollment)
Number of subjects: 323
Study 24950666 — intervention group
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa (9-60 U/kg body weight, every 2 weeks)
Number of subjects: 31
Study 24950666 — intervention group
Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa
Number of subjects: 31
Study 24950779 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (125 mg/day for 6 weeks)
Number of subjects: 59
Study 24950779 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study 24950819 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the nucleus accumbens (Acb) from M1 to M5
Number of subjects: 6
Study 24950819 — intervention group
Group type: COMPARATOR
Intervention: Deep brain stimulation (DBS) of the caudate nucleus for nonresponders between M5 and M9
Number of subjects: 6
Study 24950819 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension phase with stimulation of the Acb target for all patients
Number of subjects: 6
Study 24950819 — intervention group
Group type: EXPERIMENTAL
Intervention: Acb stimulation
Number of subjects: 6
Study 24950912 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective home monitoring based on daily assessment of FEV1 and electronic symptom score
Number of subjects: 96
Study 24950912 — intervention group
Group type: COMPARATOR
Intervention: Asthma Control Questionnaire (ACQ) with retrospective assessment of symptoms and FEV1
Number of subjects: 96
Study 24951039 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-self-reported modifiable risk factors (blood pressure, total cholesterol, high-density lipoprotein cholesterol, smoking, BMI, and HbA1c)
Number of subjects: 2359
Study 24951039 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiometabolic general CVD risk model
Number of subjects: 2359
Study 24951123 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 302
Study 24952265 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week aerobic exercise program (cycling twice a week for an hour)
Number of subjects: 26
Study 24952730 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors (TKIs)
Number of subjects: 0
Study 24952730 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel combination therapies targeting AKT/PI3K pathways
Number of subjects: 0
Study 24952730 — intervention group
Group type: EXPERIMENTAL
Intervention: mTOR inhibitors
Number of subjects: 0
Study 24952730 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib and regorafenib (VEGFR targeting drugs)
Number of subjects: 0
Study 24952730 — intervention group
Group type: EXPERIMENTAL
Intervention: CTLA4 and PD-1/PD-L1 antibodies
Number of subjects: 0
Study 24952730 — intervention group
Group type: EXPERIMENTAL
Intervention: Older agents
Number of subjects: 0
Study 24953487 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1617
Study 24953566 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 100 mg/m² days 1 and 8, cisplatin 75 mg/m² day 1, 5-fluorouracil 1000 mg/m²/day for 96 hours days 1-4, every 3 weeks for three cycles
Number of subjects: 17
Study 24953566 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent carboplatin (AUC 1.5 weekly) with radiation therapy (70 Gy/35 fractions)
Number of subjects: 17
Study 24954193 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature acclimation at 19 °C
Number of subjects: 5
Study 24954193 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature acclimation at 24 °C
Number of subjects: 5
Study 24954193 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature acclimation at 27 °C
Number of subjects: 5
Study 24954491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track surgery for THA and TKA
Number of subjects: 153
Study 24954491 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as an independent predictor
Number of subjects: 153
Study 24954791 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix (240mg starting dose, then 80mg once a month for 6 months)
Number of subjects: 213
Study 24956535 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP4 levels in HGCS (51.44 ± 16.23 mg/L)
Number of subjects: 225
Study 24956535 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentin-1 levels in HGCS (490.41 ± 172 ng/ml)
Number of subjects: 225
Study 24956535 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP4 and hsCRP as independent determinants of TPA
Number of subjects: 225
Study 24956535 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum levels of omentin-1
Number of subjects: 225
Study 24957163 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT (two cycles of the DEP regimen every 4 wk with concurrent 5040 cGy radiation in 28 fractions for 5 wk)
Number of subjects: 62
Study 24957163 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation DVIP (two cycles every 4 wk after CCRT)
Number of subjects: 62
Study 24957163 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT plus consolidation chemotherapy
Number of subjects: 62
Study 24957314 — intervention group
Group type: EXPERIMENTAL
Intervention: IV-TPA (3-4.5 hours)
Number of subjects: 723
Study 24957534 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200mg) followed by Misoprostol (800μg buccal)
Number of subjects: 1000
Study 24957547 — intervention group
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Number of subjects: 737
Study 24957547 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 737
Study 24958581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment and mental health disorders assessment
Number of subjects: 73
Study 24958581 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 73
Study 24958808 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of zoledronic acid
Number of subjects: 29
Study 24960254 — intervention group
Group type: EXPERIMENTAL
Intervention: mGluR5 negative allosteric modulators (NAMs) coadministered with L-DOPA
Number of subjects: 0
Study 24960254 — intervention group
Group type: COMPARATOR
Intervention: L-DOPA
Number of subjects: 0
Study 24960544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (10,000 IU weekly)
Number of subjects: 66
Study 24961159 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in Social Affect (SA) calibrated severity score
Number of subjects: 70
Study 24961159 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal cognitive ability
Number of subjects: 70
Study 24961159 — intervention group
Group type: EXPERIMENTAL
Intervention: ADOS overall level of language item
Number of subjects: 70
Study 24961159 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in Restricted and Repetitive Behaviors (RRB) severity score
Number of subjects: 70
Study 24961662 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir (TMC435) 100 mg once daily with PEG IFN-α-2b/RBV
Number of subjects: 79
Study 24961747 — intervention group
Group type: EXPERIMENTAL
Intervention: H1N1 vaccine
Number of subjects: 78
Study 24962156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging (CMR) parameters including infarct size, microvascular obstruction (MO), myocardial salvage index (MSI), and left ventricular ejection fraction (LV-EFCMR).
Number of subjects: 278
Study 24962156 — intervention group
Group type: COMPARATOR
Intervention: Traditional outcome markers including ST-segment resolution, pre- and post-PCI TIMI-flow, maximum level of creatine kinase-MB, TIMI-risk score, and left ventricular ejection fraction assessed by echocardiography.
Number of subjects: 278
Study 24962750 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib
Number of subjects: 185
Study 24962750 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib+HBV
Number of subjects: 185
Study 24963042 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine/melphalan (FluMel) as a preparative regimen for sibling donors
Number of subjects: 66
Study 24963042 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine/melphalan (FluMel) plus anti-thymocyte globulin (ATG) for unrelated donors
Number of subjects: 66
Study 24963043 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib 56 mg/m2
Number of subjects: 44
Study 24963043 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib 56 mg/m2 + Dexamethasone (20 mg)
Number of subjects: 44
Study 24963112 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of PCB153
Number of subjects: 0
Study 24963112 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of PCBs
Number of subjects: 0
Study 24963112 — intervention group
Group type: EXPERIMENTAL
Intervention: p,p'-DDE
Number of subjects: 0
Study 24963112 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue levels of p,p'-DDE
Number of subjects: 0
Study 24963112 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of PCBs
Number of subjects: 0
Study 24963112 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum and adipose tissue levels of all POPs
Number of subjects: 0
Study 24963497 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose decitabine-based chemoimmunotherapy
Number of subjects: 0
Study 24964010 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-min break after 30 SED min
Number of subjects: 30
Study 24964010 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min break after 60 SED min
Number of subjects: 30
Study 24964010 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-min break after 120 SED min
Number of subjects: 30
Study 24964084 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71-C4a vaccine
Number of subjects: 0
Study 24964084 — intervention group
Group type: EXPERIMENTAL
Intervention: New pseudovirus-based neutralization assay
Number of subjects: 0
Study 24964317 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon Capsule Endoscopy (CCE)
Number of subjects: 100
Study 24964317 — intervention group
Group type: COMPARATOR
Intervention: CT Colonography (CTC)
Number of subjects: 100
Study 24964817 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET
Number of subjects: 30
Study 24964817 — intervention group
Group type: EXPERIMENTAL
Intervention: (123)I-mIBG scintigraphy
Number of subjects: 30
Study 24964817 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up (18)F-FDG PET
Number of subjects: 30
Study 24964817 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up (123)I-mIBG scintigraphy
Number of subjects: 30
Study 24964817 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial altered cardiac metabolism
Number of subjects: 30
Study 24964991 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-culture virus-specific T cells (VSTs) targeting 12 immunogenic antigens from five viruses (AdV, EBV, CMV, BKV, HHV6)
Number of subjects: 11
Study 24965302 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma di-homo-γ-linolenic acid
Number of subjects: 51
Study 24965748 — intervention group
Group type: EXPERIMENTAL
Intervention: Orteronel 300 mg twice daily until PSA progression, metastases, or unacceptable toxicity.
Number of subjects: 39
Study 24965999 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral laparoscopic ovarian drilling with thermal doses adjusted to ovarian volume: median of 720J (IQR)
Number of subjects: 96
Study 24965999 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral drilling with fixed doses of 1200J
Number of subjects: 96
Study 24965999 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (unilateral and bilateral diathermy)
Number of subjects: 96
Study 24965999 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline value of T
Number of subjects: 96
Study 24965999 — intervention group
Group type: EXPERIMENTAL
Intervention: Value of T in the 1st month after diathermy
Number of subjects: 96
Study 24966061 — intervention group
Group type: EXPERIMENTAL
Intervention: ELLIPTA dry powder inhaler
Number of subjects: 0
Study 24966061 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 24966411 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytase added to maize porridge immediately before consumption or used for dephytinization during meal preparation
Number of subjects: 0
Study 24966411 — intervention group
Group type: EXPERIMENTAL
Intervention: Na2EDTA at an EDTA:zinc molar ratio of 1:1
Number of subjects: 0
Study 24966411 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (ZnSO4)
Number of subjects: 0
Study 24966411 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorghum polyphenols
Number of subjects: 0
Study 24967217 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus gastroenteritis (RVGE) hospitalizations
Number of subjects: 1222
Study 24967217 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus gastroenteritis (RVGE) ER visits
Number of subjects: 1222
Study 24967217 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-acquired AGE cases due to RV
Number of subjects: 1222
Study 24967217 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of nosocomial RVGE
Number of subjects: 1222
Study 24967217 — intervention group
Group type: EXPERIMENTAL
Intervention: Median duration of hospitalization among RV-positive subjects
Number of subjects: 1222
Study 24967217 — intervention group
Group type: EXPERIMENTAL
Intervention: Median duration for additional hospitalization due to nosocomial RVGE
Number of subjects: 1222
Study 24967217 — intervention group
Group type: EXPERIMENTAL
Intervention: Burden of nosocomial RVGE in children aged 12-23 months
Number of subjects: 1222
Study 24967244 — intervention group
Group type: EXPERIMENTAL
Intervention: Living kidney donation
Number of subjects: 81
Study 24969309 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n=72)
Number of subjects: 180
Study 24969506 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin within 24 hours
Number of subjects: 12264
Study 24969506 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 12264
Study 24969506 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 12264
Study 24969506 — intervention group
Group type: COMPARATOR
Intervention: Proportion of patients who did not receive reperfusion
Number of subjects: 12264
Study 24969506 — intervention group
Group type: EXPERIMENTAL
Intervention: Median length of hospital stay
Number of subjects: 12264
Study 24969506 — intervention group
Group type: COMPARATOR
Intervention: Adjusted in-hospital mortality
Number of subjects: 12264
Study 24969516 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline monohydrate, 50 mg/d for 24 months
Number of subjects: 33
Study 24969516 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 months
Number of subjects: 33
Study 24969797 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hyperfractionated radiation therapy (36 Gy to craniospinal axis, 68 Gy to tumor region, 72 Gy to residual tumor, fractionated at 2 × 1 Gy per day 5 days per week) followed by maintenance chemotherapy (lomustine, cisplatin, and vincristine)
Number of subjects: 26
Study 24969797 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hyperfractionated radiation therapy followed by maintenance chemotherapy
Number of subjects: 26
Study 24970095 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote grading of images by trained nonphysician readers
Number of subjects: 1257
Study 24970095 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote grading of images considering both eyes
Number of subjects: 1257
Study 24970095 — intervention group
Group type: COMPARATOR
Intervention: Criterion standard diagnostic examination
Number of subjects: 1257
Study 24970468 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC-I/H)
Number of subjects: 1050
Study 24970468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1050
Study 24970686 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% saline infusion
Number of subjects: 23
Study 24970773 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram, sertraline, or extended-release venlafaxine (8-week course)
Number of subjects: 102
Study 24970773 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (no specific intervention mentioned)
Number of subjects: 102
Study 24970782 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-duration rivaroxaban
Number of subjects: 2593
Study 24970782 — intervention group
Group type: COMPARATOR
Intervention: Standard-duration enoxaparin followed by placebo
Number of subjects: 2593
Study 24970846 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS-immunization with Plasmodium falciparum sporozoites
Number of subjects: 38
Study 24970906 — intervention group
Group type: EXPERIMENTAL
Intervention: FBB+ (positive FBB defined by SUVR ≥ 1.45)
Number of subjects: 45
Study 24970906 — intervention group
Group type: COMPARATOR
Intervention: FBB- (negative FBB)
Number of subjects: 45
Study 24970906 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal volume (HV)
Number of subjects: 45
Study 24970906 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnestic MCI (aMCI) status
Number of subjects: 45
Study 24970932 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1*07:01 alleles
Number of subjects: 1870
Study 24970932 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1 alleles predicted high-affinity binding
Number of subjects: 1870
Study 24972362 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine up to 60 mg/d
Number of subjects: 28
Study 24972362 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine up to 120 mg/d
Number of subjects: 28
Study 24972362 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine added to tranylcypromine
Number of subjects: 28
Study 24972362 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline + lithium
Number of subjects: 28
Study 24972362 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine added to nortriptyline + lithium
Number of subjects: 28
Study 24972362 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 28
Study 24972362 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance of remission
Number of subjects: 28
Study 24972632 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-lentil RUSF
Number of subjects: 90
Study 24972632 — intervention group
Group type: EXPERIMENTAL
Intervention: Chickpea-based RUSF
Number of subjects: 90
Study 24972632 — intervention group
Group type: COMPARATOR
Intervention: Pushti packet (control)
Number of subjects: 90
Study 24972632 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-lentil RUSF and Chickpea-based RUSF
Number of subjects: 90
Study 24973461 — intervention group
Group type: EXPERIMENTAL
Intervention: A/turkey/Turkey/1/2005(H5N1)-AS03B (booster vaccination)
Number of subjects: 113
Study 24973461 — intervention group
Group type: COMPARATOR
Intervention: A/Indonesia/05/2005(H5N1)-AS03B (primary vaccination)
Number of subjects: 113
Study 24973924 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous Vein Y-composite graft (SV group, n = 112)
Number of subjects: 224
Study 24973924 — intervention group
Group type: COMPARATOR
Intervention: Right Internal Thoracic Artery Y-composite graft (RITA group, n = 112)
Number of subjects: 224
Study 24973924 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous Vein composite grafts
Number of subjects: 224
Study 24973924 — intervention group
Group type: COMPARATOR
Intervention: Right Internal Thoracic Artery composite grafts
Number of subjects: 224
Study 24973924 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rates
Number of subjects: 224
Study 24973924 — intervention group
Group type: EXPERIMENTAL
Intervention: Freedom from major adverse cardiac and cerebrovascular events
Number of subjects: 224